Universal Germline and Somatic Testing for All Newly Diagnosed Breast Cancer

Published Alicia Mew on Wed, 09/06/2023 - 13:45

VCCC Alliance Breast Cancer Grand Round with Dr Dilanka De Silva

Universal Germline and Somatic Testing for All Newly Diagnosed Breast Cancer

09 Aug 2023

The current standard of care for breast cancer testing may not be enough. Are we missing pathogenic actionable germline variants? Unravel the mysteries of germline testing in breast cancer with Dr Dilanka De Silva, and hear new insights emerging from the ground-breaking MAGIC study.

The Mutational Assessment of newly diagnosed breast cancer using Germline and tumour genomics (MAGIC) study is the first of its kind in Australia to challenge the status quo of the existing standard of breast cancer care. It evaluates the prevalence of pathogenic germline variants in the Australian breast cancer population and the accuracy of its detection compared to current methods.

The implications of timely result delivery on clinical management, the psychosocial acceptability of universal germline testing, and the potential effects of combined germline and somatic information on patient management are all integral aspects of this transformative study.

Aim: to present new insights gained from The Mutational Assessment of newly diagnosed breast cancer using Germline and tumour genomics (MAGIC) study. 

Learning objective:  In this session, you will gain insights into if we are missing pathogenic actionable germline variants as the MAGIC study says yes, by more than 50%.

Dr Dilanka De Silva

Dr Dilanka De Silva
PhD Candidate, the University of Melbourne; Honorary Medical Oncologist,Parkville Familial Cancer Centre

As a PhD Candidate at the University of Melbourne and an Honorary Medical Oncologist at Parkville FCC, Dr Dilanka De Silva brings his extensive experience in Breast Cancer genetics to this discussion. Having worked in a diverse range of settings – from regional to high-volume tertiary centres – and being certified to practise Medicine and Oncology in the United States, United Kingdom, Australia, and New Zealand, Dr De Silva has a unique global perspective. His keen interest in early drug development, liquid biopsies, and HER2 therapy was developed during his prestigious Fellowship at the Memorial Sloan Kettering Cancer Centre in New York, USA.

Course Details

test tube
Course type
Webinars
Duration
60 mins
Price
$0.00
Curriculum Area
Prevention, screening and diagnostics
Speciality
Early to mid career researcher
Clinician
Breast
Genomics

This course is brought to you by

Alliance members